Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 107
Filtrer
1.
Sci Rep ; 11(1): 14961, 2021 07 22.
Article de Anglais | MEDLINE | ID: mdl-34294757

RÉSUMÉ

Influenza and other respiratory viruses present a significant threat to public health, national security, and the world economy, and can lead to the emergence of global pandemics such as from COVID-19. A barrier to the development of effective therapeutics is the absence of a robust and predictive preclinical model, with most studies relying on a combination of in vitro screening with immortalized cell lines and low-throughput animal models. Here, we integrate human primary airway epithelial cells into a custom-engineered 96-device platform (PREDICT96-ALI) in which tissues are cultured in an array of microchannel-based culture chambers at an air-liquid interface, in a configuration compatible with high resolution in-situ imaging and real-time sensing. We apply this platform to influenza A virus and coronavirus infections, evaluating viral infection kinetics and antiviral agent dosing across multiple strains and donor populations of human primary cells. Human coronaviruses HCoV-NL63 and SARS-CoV-2 enter host cells via ACE2 and utilize the protease TMPRSS2 for spike protein priming, and we confirm their expression, demonstrate infection across a range of multiplicities of infection, and evaluate the efficacy of camostat mesylate, a known inhibitor of HCoV-NL63 infection. This new capability can be used to address a major gap in the rapid assessment of therapeutic efficacy of small molecules and antiviral agents against influenza and other respiratory viruses including coronaviruses.


Sujet(s)
Antiviraux/pharmacologie , Infections à coronavirus/virologie , Grippe humaine/virologie , Tests de sensibilité microbienne/instrumentation , Techniques d'analyse microfluidique/instrumentation , Muqueuse respiratoire/cytologie , Bronches/cytologie , Bronches/virologie , COVID-19/virologie , Techniques de culture cellulaire/instrumentation , Lignée cellulaire , Coronavirus/effets des médicaments et des substances chimiques , Infections à coronavirus/traitement médicamenteux , Conception d'appareillage , Tests de criblage à haut débit/instrumentation , Humains , Virus de la grippe A/effets des médicaments et des substances chimiques , Grippe humaine/traitement médicamenteux , Muqueuse respiratoire/virologie , Infections de l'appareil respiratoire/traitement médicamenteux , Infections de l'appareil respiratoire/virologie , SARS-CoV-2/effets des médicaments et des substances chimiques , Traitements médicamenteux de la COVID-19
2.
J Hosp Infect ; 96(3): 244-249, 2017 Jul.
Article de Anglais | MEDLINE | ID: mdl-28454768

RÉSUMÉ

BACKGROUND: Contact precautions are a widely accepted strategy to reduce in-hospital transmission of meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). However, these practices may have unintended deleterious effects on patients. AIM: To evaluate the effect of a modification in hospital-wide contact precaution practices on emergency department (ED) admission times. METHODS: During the study period, the hospital changed its contact precaution policy from requiring contact precautions for all patients with a history of MRSA or VRE to only those who presented with clinical conditions likely to contaminate the environment with pathogens. An interrupted time series analysis of ED admission times for adults for one year preceding and one year following this change was performed at a two-campus hospital. The main outcome was admission time, defined as time from decision to admit to arrival in an inpatient bed, for patients with MRSA or VRE compared with all other patients. The in-hospital MRSA and VRE acquisition rates were evaluated over the same period and have been published previously. FINDINGS: At one campus, admission time decreased immediately by 161min for MRSA patients (P=0.008) and 135min for VRE patients (P=0.003), and both continued to decrease over the duration of the study. There was no significant change in admission time at the second campus. CONCLUSIONS: Modifying contact precaution requirements for MRSA and VRE may be associated with improved ED admission time without significantly altering in-hospital MRSA and VRE acquisition.


Sujet(s)
Infection croisée/prévention et contrôle , Médecine d'urgence/méthodes , Infections bactériennes à Gram positif/diagnostic , Prévention des infections/méthodes , Staphylococcus aureus résistant à la méticilline/isolement et purification , Admission du patient , Entérocoques résistants à la vancomycine/isolement et purification , Adulte , État de porteur sain/diagnostic , Service hospitalier d'urgences , Hôpitaux , Humains , Politique organisationnelle , Études rétrospectives , Facteurs temps
3.
Am J Transplant ; 13(4): 1047-1054, 2013 Apr.
Article de Anglais | MEDLINE | ID: mdl-23356386

RÉSUMÉ

Rapid allograft infection complicates liver transplantation (LT) in patients with hepatitis C virus (HCV). Pegylated interferon-α and ribavirin therapy after LT has significant toxicity and limited efficacy. The effect of a human monoclonal antibody targeting the HCV E2 glycoprotein (MBL-HCV1) on viral clearance was examined in a randomized, double-blind, placebo-controlled pilot study in patients infected with HCV genotype 1a undergoing LT. Subjects received 11 infusions of 50 mg/kg MBL-HCV1 (n=6) or placebo (n=5) intravenously with three infusions on day of transplant, a single infusion on days 1 through 7 and one infusion on day 14 after LT. MBL-HCV1 was well-tolerated and reduced viral load for a period ranging from 7 to 28 days. Median change in viral load (log10 IU/mL) from baseline was significantly greater (p=0.02) for the antibody-treated group (range -3.07 to -3.34) compared to placebo group (range -0.331 to -1.01) on days 3 through 6 posttransplant. MBL-HCV1 treatment significantly delayed median time to viral rebound compared to placebo treatment (18.7 days vs. 2.4 days, p<0.001). As with other HCV monotherapies, antibody-treated subjects had resistance-associated variants at the time of viral rebound. A combination study of MBL-HCV1 with a direct-acting antiviral is underway.


Sujet(s)
Anticorps monoclonaux/pharmacologie , Hepacivirus/physiologie , Hépatite C/traitement médicamenteux , Transplantation hépatique , Sujet âgé , Biopsie , Méthode en double aveugle , Femelle , Génotype , Hépatite C/virologie , Humains , Foie/anatomopathologie , Mâle , Adulte d'âge moyen , Projets pilotes , ARN viral/analyse , Facteurs temps , Protéines de l'enveloppe virale/immunologie
4.
Clin Exp Immunol ; 140(2): 230-40, 2005 May.
Article de Anglais | MEDLINE | ID: mdl-15807846

RÉSUMÉ

Complement receptor 1 (CR1) on the surface of human erythrocytes facilitates intravascular clearance of complement-opsonized pathogens. The need for complement activation can be circumvented by directly coupling the organism to CR1 using a bispecific monoclonal antibody heteropolymer (HP). Lack of a functional homologue to CR1 on mouse erythrocytes has made it difficult to study HP-dependent clearance of pathogens in small animals. We have developed a transgenic mouse that expresses human CR1 on erythrocytes. CR1 antigen is of appropriate size and in a clustered distribution as confirmed by immunoblotting and fluorescence microscopy, respectively. HP that immobilized bacteriophage PhiX174 prototype pathogen to erythrocyte CR1 of the transgenic mice increased the rate of clearance of the virus compared with HP that bound bacteriophage, but not CR1. This transgenic mouse model will allow evaluation of different HPs for their in vivo efficacy and potential as human therapeutics.


Sujet(s)
Anticorps bispécifiques/immunologie , Pathogènes transmissibles par le sang , Modèles animaux de maladie humaine , Récepteurs au complément/immunologie , Animaux , Complexe antigène-anticorps/immunologie , Bactériophage phi X-174/immunologie , Relation dose-réponse (immunologie) , Érythrocytes/immunologie , Humains , Souris , Souris de lignée C57BL , Souris transgéniques , Microscopie de fluorescence , Papio
5.
J Virol ; 75(22): 10730-7, 2001 Nov.
Article de Anglais | MEDLINE | ID: mdl-11602714

RÉSUMÉ

The mammalian Toll-like receptor 4, TLR4, is an important component in the innate immune response to gram-negative bacterial infection. The role of TLR4 in antiviral immunity has been largely unexplored. In this study, the in vivo immune responses to respiratory syncytial virus (RSV) and influenza virus infection were examined in TLR4-deficient (C57BL/10ScNCr) and TLR4-expressing (C57BL/10Sn) mice. TLR4-deficient mice challenged with RSV, but not influenza virus, exhibited impaired natural killer (NK) cell and CD14(+) cell pulmonary trafficking, deficient NK cell function, impaired interleukin-12 expression, and impaired virus clearance compared to mice expressing TLR4. These findings suggest that Toll signaling pathways have an important role in innate immunity to RSV.


Sujet(s)
Protéines de Drosophila , Glycoprotéines membranaires/physiologie , Récepteurs de surface cellulaire/physiologie , Infections à virus respiratoire syncytial/immunologie , Animaux , Cytotoxicité immunologique , Femelle , Immunité innée , Interleukine-12/physiologie , Interleukine-18/physiologie , Cellules tueuses naturelles/immunologie , Antigènes CD14/analyse , Poumon/immunologie , Poumon/anatomopathologie , Souris , Souris de lignée C57BL , Lymphocytes T cytotoxiques/immunologie , Récepteur de type Toll-4 , Récepteurs de type Toll
6.
Curr Opin Oncol ; 13(5): 349-53, 2001 Sep.
Article de Anglais | MEDLINE | ID: mdl-11555711

RÉSUMÉ

Epstein-Barr virus (EBV), a human herpes virus, is associated with a variety of malignancies. In vitro, it is able to transform B cells, which will grow as lymphoblastoid cell lines in the absence of T cells. Patients with a variety of immunodeficiency diseases are subject to the development of B-cell lymphomas that express viral antigens on their cell surface. Development of EBV-associated B-cell lymphomas is seen in solid organ transplant and bone marrow transplant recipients receiving immunosuppressive therapy. Transfer of mature T cells from EBV-immune marrow donors has been demonstrated to be effective in controlling these EBV-associated B-cell tumors. Recently the demonstration that EBV transcripts are found in other lymphomas (including Hodgkin disease cells) has led to the suggestion that transfer of EBV-specific T cells may also be effective in managing these tumors. Current research involves optimizing methods to expand cells that recognize the EBV antigens expressed in the lymphoma cells.


Sujet(s)
Infections à virus Epstein-Barr/complications , Herpèsvirus humain de type 4/immunologie , Lymphome B/virologie , Lymphocytes T/virologie , Antigènes viraux , Humains , Sujet immunodéprimé , Immunosuppresseurs/effets indésirables , Immunosuppresseurs/usage thérapeutique , Lymphome B/immunologie , Lymphome B/thérapie , Transplantation d'organe/effets indésirables , Lymphocytes T/immunologie
7.
Infect Immun ; 68(12): 6650-5, 2000 Dec.
Article de Anglais | MEDLINE | ID: mdl-11083777

RÉSUMÉ

Abscesses are a classic host response to infection by many pathogenic bacteria. The immunopathogenesis of this tissue response to infection has not been fully elucidated. Previous studies have suggested that T cells are involved in the pathologic process, but the role of these cells remains unclear. To delineate the mechanism by which T cells mediate abscess formation associated with intra-abdominal sepsis, the role of T-cell activation and the contribution of antigen-presenting cells via CD28-B7 costimulation were investigated. T cells activated in vitro by zwitterionic bacterial polysaccharides (Zps) known to induce abscess formation required CD28-B7 costimulation and, when adoptively transferred to the peritoneal cavity of naïve rats, promoted abscess formation. Blockade of T-cell activation via the CD28-B7 pathway in animals with CTLA4Ig prevented abscess formation following challenge with different bacterial pathogens, including Staphylococcus aureus, Bacteroides fragilis, and a combination of Enterococcus faecium and Bacteroides distasonis. In contrast, these animals had an increased abscess rate following in vivo T-cell activation via CD28 signaling. Abscess formation in vivo and T-cell activation in vitro required costimulation by B7-2 but not B7-1. These results demonstrate that abscess formation by pathogenic bacteria is under the control of a common effector mechanism that requires T-cell activation via the CD28-B7-2 pathway.


Sujet(s)
Abcès/étiologie , Antigènes CD/physiologie , Antigène CD28/physiologie , Lymphocytes T CD4+/immunologie , Immunoconjugués , Activation des lymphocytes , Glycoprotéines membranaires/physiologie , Abatacept , Animaux , Antigènes de différenciation/pharmacologie , Antigène CD80/physiologie , Antigène CD86 , Antigène CTLA-4 , Humains , Mâle , Rats , Rat Wistar
8.
Virology ; 271(1): 99-108, 2000 May 25.
Article de Anglais | MEDLINE | ID: mdl-10814575

RÉSUMÉ

Group B coxsackieviruses are etiologically linked to many human diseases, and cell surface receptors are postulated to play an important role in mediating their pathogenesis. The coxsackievirus adenovirus receptor (CAR) has been shown to function as a receptor for selected strains of coxsackievirus group B (CVB) serotypes 3, 4, and 5 and is postulated to serve as a receptor for all six serotypes. In this study, we demonstrate that CAR can serve as a receptor for laboratory reference strains and clinical isolates of all six CVB serotypes. Infection of CHO cells expressing human CAR results in a 1000-fold increase in CVB progeny virus titer compared to mock transfected cells. CAR was shown to be a functional receptor for swine vesicular disease virus (SVDV), as CHO-CAR cells but not CHO mock transfected controls were susceptible to SVDV infection, produced progeny SVDV, and developed cytopathic effects. Moreover, SVDV infection could be specifically blocked by monoclonal antibody to CAR (RmcB). SVDV infection of HeLa cells was also inhibited by an anti-CD55 MAb, suggesting that this virus, like some CVB, may interact with CD55 (decay accelerating factor) in addition to CAR. Finally, pretreatment of CVB or SVDV with soluble CAR effectively blocks virus infection of HeLa cell monolayers.


Sujet(s)
Entérovirus humain B/classification , Récepteurs viraux/physiologie , Maladie vésiculeuse des suidés/virologie , Animaux , Antigènes CD55/métabolisme , Cellules CHO , Chlorocebus aethiops , Protéine membranaire apparentée au récepteur des coxsackievirus et adénovirus , Cricetinae , Effet cytopathogène viral , Cellules HeLa , Humains , Réaction de polymérisation en chaîne , Sérotypie , Suidae , Transfection , Cellules Vero
9.
J Biol Chem ; 275(10): 6733-40, 2000 Mar 10.
Article de Anglais | MEDLINE | ID: mdl-10702228

RÉSUMÉ

Immunologic paradigms classify bacterial polysaccharides as T cell-independent antigens. However, these models fail to explain how zwitterionic polysaccharides (Zps) confer protection against intraabdominal abscess formation in a T cell-dependent manner. Here, we demonstrate that Zps elicit a potent CD4+ T cell response in vitro that requires available major histocompatibility complex class II molecules on antigen-presenting cells. Specific chemical modifications to Zps show that: 1) the activity is specific for carbohydrate structure, and 2) the proliferative response depends upon free amino and carboxyl groups on the repeating units of these polysaccharides. Peptides synthesized to mimic the zwitterionic charge motif associated with Zps also exhibited these biologic properties. Lysine-aspartic acid (KD) peptides with more than 15 repeating units stimulated CD4+ T cells in vitro and conferred protection against abscesses induced by bacteria such as Bacteroides fragilis and Staphylococcus aureus. Evidence for the biologic importance of T cell activation by these zwitterionic polymers was provided when human CD4+ T cells stimulated with these molecules in vitro and adoptively transferred to rats in vivo conferred protection against intraabdominal abscesses induced by viable bacterial challenge. These studies demonstrate that bacterial polysaccharides with a distinct charge motif activate T cells and that this activity confers immunity to a distinct pathologic response to bacterial infection.


Sujet(s)
Abcès/prévention et contrôle , Activation des lymphocytes/effets des médicaments et des substances chimiques , Polyosides bactériens/pharmacologie , Lymphocytes T/effets des médicaments et des substances chimiques , Animaux , Bacteroides fragilis/immunologie , Techniques in vitro , Mâle , Peptides/pharmacologie , Rats , Rats de lignée LEW , Streptococcus pneumoniae/immunologie , Relation structure-activité , Lymphocytes T/immunologie
10.
Nat Med ; 6(4): 435-42, 2000 Apr.
Article de Anglais | MEDLINE | ID: mdl-10742151

RÉSUMÉ

Here, we demonstrate a previously unknown function for the 70-kDa heat-shock protein (HSP70) as a cytokine. HSP70 bound with high affinity to the plasma membrane, elicited a rapid intracellular calcium flux, activated nuclear factor (NF)-kappaB and upregulated the expression of pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-6 in human monocytes. Furthermore, two different signal transduction pathways were activated by exogenous HSP70: one dependent on CD14 and intracellular calcium, which resulted in increased IL-1beta, IL-6 and TNF-alpha; and the other independent of CD14 but dependent on intracellular calcium, which resulted in an increase in TNF-alpha but not IL-1beta or IL-6. These findings indicate that CD14 is a co-receptor for HSP70-mediated signaling in human monocytes and are indicative of an previously unrecognized function for HSP70 as an extracellular protein with regulatory effects on human monocytes, having a dual role as chaperone and cytokine.


Sujet(s)
Protéines du choc thermique HSP70/immunologie , Protéines I-kappa B , Interleukine-1/biosynthèse , Interleukine-6/biosynthèse , Facteur de nécrose tumorale alpha/biosynthèse , Calcium/immunologie , Cellules cultivées , Cytokines/immunologie , Cytokines/physiologie , Protéines de liaison à l'ADN/immunologie , Protéines de liaison à l'ADN/métabolisme , Protéines du choc thermique HSP70/pharmacologie , Humains , Antigènes CD14/immunologie , Monocytes/cytologie , Monocytes/effets des médicaments et des substances chimiques , Monocytes/immunologie , Inhibiteur alpha de NF-KappaB , Facteur de transcription NF-kappa B/antagonistes et inhibiteurs , Cellules cancéreuses en culture
11.
J Clin Invest ; 105(4): 497-504, 2000 Feb.
Article de Anglais | MEDLINE | ID: mdl-10683379

RÉSUMÉ

Lipopolysaccharide (LPS) is the main inducer of shock and death in Gram-negative sepsis. Recent evidence suggests that LPS-induced signal transduction begins with CD14-mediated activation of 1 or more Toll-like receptors (TLRs). The lipid A analogues lipid IVa and Rhodobacter sphaeroides lipid A (RSLA) exhibit an uncommon species-specific pharmacology. Both compounds inhibit the effects of LPS in human cells but display LPS-mimetic activity in hamster cells. We transfected human TLR4 or human TLR2 into hamster fibroblasts to determine if either of these LPS signal transducers is responsible for the species-specific pharmacology. RSLA and lipid IVa strongly induced NF-kappaB activity and IL-6 release in Chinese hamster ovary fibroblasts expressing CD14 (CHO/CD14), but these compounds antagonized LPS antagonists in CHO/CD14 fibroblasts that overexpressed human TLR4. No such antagonism occurred in cells overexpressing human TLR2. We cloned TLR4 from hamster macrophages and found that human THP-1 cells expressing the hamster TLR4 responded to lipid IVa as an LPS mimetic, as if they were hamster in origin. Hence, cells heterologously overexpressing TLR4 from different species acquired a pharmacological phenotype with respect to recognition of lipid A substructures that corresponded to the species from which the TLR4 transgene originated. These data suggest that TLR4 is the central lipid A-recognition protein in the LPS receptor complex.


Sujet(s)
Protéines de Drosophila , Antigènes CD14/métabolisme , Lipopolysaccharides/métabolisme , Glycoprotéines membranaires/métabolisme , Récepteurs de surface cellulaire/métabolisme , Animaux , Cellules CHO , Cricetinae , Glycolipides/métabolisme , Humains , Ligands , Lipide A/analogues et dérivés , Lipide A/métabolisme , Antigènes CD14/génétique , Lipopolysaccharides/antagonistes et inhibiteurs , Macrophages/cytologie , Macrophages/métabolisme , Glycoprotéines membranaires/génétique , Mimétisme moléculaire , Récepteurs de surface cellulaire/génétique , Protéines recombinantes/métabolisme , Rhodobacter sphaeroides , Transduction du signal , Spécificité d'espèce , Récepteur de type Toll-2 , Récepteur de type Toll-4 , Récepteurs de type Toll
12.
J Immunol ; 164(2): 719-24, 2000 Jan 15.
Article de Anglais | MEDLINE | ID: mdl-10623815

RÉSUMÉ

The large-molecular-sized zwitterionic capsular polysaccharide of the anaerobe Bacteroides fragilis NCTC 9343, designated polysaccharide (PS) A, stimulates T cell proliferation in vitro and induces T cell-dependent protection against abscess formation in vivo. In the present study, we utilized a modification of a recently developed ozonolytic method for depolymerizing polysaccharides to examine the influence of the molecular size of PS A on cell-mediated immunity. Ozonolysis successfully depolymerized PS A into structurally intact fragments. PS A with average molecular sizes of 129.0 (native), 77.8, 46.9, and 17.1 kDa stimulated CD4+-cell proliferation in vitro to the same degree, whereas the 5.0-kDa fragment was much less stimulatory than the control 129.0-kDa PS A. Rats treated with 129.0-kDa, 46.9-kDa, and 17.1-kDa PS A molecules, but not those treated with the 5.0-kDa molecule, were protected against intraabdominal abscesses induced by challenge with viable B. fragilis. These results demonstrate that a zwitterionic polysaccharide as small as 22 repeating units (88 monosaccharides) elicits a T cell-dependent immune response. These findings clearly distinguish zwitterionic T cell-dependent polysaccharides from T cell-independent polysaccharides and give evidence of the existence of a novel mechanism for a polysaccharide-induced immune response.


Sujet(s)
Activation des lymphocytes/immunologie , Polyosides bactériens/composition chimique , Polyosides bactériens/immunologie , Abcès abdominal/immunologie , Abcès abdominal/prévention et contrôle , Animaux , Infections à Bacteroides/immunologie , Infections à Bacteroides/prévention et contrôle , Bacteroides fragilis/immunologie , Substances tampon , Séquence glucidique , Cellules cultivées , Modèles animaux de maladie humaine , Relation dose-réponse (immunologie) , Humains , Ions , Mâle , Données de séquences moléculaires , Masse moléculaire , Polyosides bactériens/métabolisme , Rats , Rat Wistar
13.
J Immunol ; 164(1): 13-7, 2000 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-10604986

RÉSUMÉ

Heat shock proteins (HSP), highly conserved across species, are generally viewed as intracellular proteins thought to serve protective functions against infection and cellular stress. Recently, we have reported the surprising finding that human and chlamydial HSP60, both present in human atheroma, can activate vascular cells and macrophages. However, the transmembrane signaling pathways by which extracellular HSP60 may activate cells remains unclear. CD14, the monocyte receptor for LPS, binds numerous microbial products and can mediate activation of monocytes/macrophages and endothelial cells, thus promoting the innate immune response. We show here that human HSP60 activates human PBMC and monocyte-derived macrophages through CD14 signaling and p38 mitogen-activated protein kinase, sharing this pathway with bacterial LPS. These findings provide further insight into the molecular mechanisms by which extracellular HSP may participate in atherosclerosis and other inflammatory disorders by activating the innate immune system.


Sujet(s)
Chaperonine-60/physiologie , Antigènes CD14/physiologie , Activation des macrophages/immunologie , Macrophages/immunologie , Monocytes/immunologie , Animaux , Cellules CHO , Cellules cultivées , Chlamydia/immunologie , Cricetinae , Cytokines/biosynthèse , Endotoxines/physiologie , Activation enzymatique/immunologie , Gènes rapporteurs/immunologie , Humains , Immunité innée , Antigènes CD14/métabolisme , Macrophages/métabolisme , Mitogen-Activated Protein Kinases/métabolisme , Monocytes/métabolisme , Facteur de transcription NF-kappa B/génétique , Facteur de transcription NF-kappa B/métabolisme , Transduction du signal/immunologie , Cellules cancéreuses en culture , p38 Mitogen-Activated Protein Kinases
14.
Nat Immunol ; 1(5): 398-401, 2000 Nov.
Article de Anglais | MEDLINE | ID: mdl-11062499

RÉSUMÉ

The innate immune system contributes to the earliest phase of the host defense against foreign organisms and has both soluble and cellular pattern recognition receptors for microbial products. Two important members of this receptor group, CD14 and the Toll-like receptor (TLR) pattern recognition receptors, are essential for the innate immune response to components of Gram-negative and Gram-positive bacteria, mycobacteria, spirochetes and yeast. We now find that these receptors function in an antiviral response as well. The innate immune response to the fusion protein of an important respiratory pathogen of humans, respiratory syncytial virus (RSV), was mediated by TLR4 and CD14. RSV persisted longer in the lungs of infected TLR4-deficient mice compared to normal mice. Thus, a common receptor activation pathway can initiate innate immune responses to both bacterial and viral pathogens.


Sujet(s)
Protéines de Drosophila , Antigènes CD14/immunologie , Glycoprotéines membranaires/immunologie , Récepteurs de surface cellulaire/immunologie , Virus respiratoires syncytiaux/immunologie , Virus respiratoires syncytiaux/pathogénicité , Animaux , Anticorps monoclonaux/pharmacologie , Cytokines/biosynthèse , Humains , Techniques in vitro , Médiateurs de l'inflammation/métabolisme , Agranulocytes/immunologie , Antigènes CD14/génétique , Poumon/immunologie , Poumon/virologie , Glycoprotéines membranaires/déficit , Glycoprotéines membranaires/génétique , Souris , Souris knockout , Récepteurs de surface cellulaire/déficit , Récepteurs de surface cellulaire/génétique , Infections à virus respiratoire syncytial/immunologie , Infections à virus respiratoire syncytial/virologie , Récepteur de type Toll-4 , Récepteurs de type Toll , Protéines de fusion virale/immunologie
15.
J Biol Chem ; 274(47): 33419-25, 1999 Nov 19.
Article de Anglais | MEDLINE | ID: mdl-10559223

RÉSUMÉ

Toll-like receptors (TLRs) 2 and 4 are signal transducers for lipopolysaccharide, the major proinflammatory constituent in the outer membrane of Gram-negative bacteria. We observed that membrane lipoproteins/lipopeptides from Borrelia burgdorferi, Treponema pallidum, and Mycoplasma fermentans activated cells heterologously expressing TLR2 but not those expressing TLR1 or TLR4. These TLR2-expressing cells were also stimulated by living motile B. burgdorferi, suggesting that TLR2 recognition of lipoproteins is relevant to natural Borrelia infection. Importantly, a TLR2 antibody inhibited bacterial lipoprotein/lipopeptide-induced tumor necrosis factor release from human peripheral blood mononuclear cells, and TLR2-null Chinese hamster macrophages were insensitive to lipoprotein/lipopeptide challenge. The data suggest a role for the native protein in cellular activation by these ligands. In addition, TLR2-dependent responses were seen using whole Mycobacterium avium and Staphylococcus aureus, demonstrating that this receptor can function as a signal transducer for a wide spectrum of bacterial products. We conclude that diverse pathogens activate cells through TLR2 and propose that this molecule is a central pattern recognition receptor in host immune responses to microbial invasion.


Sujet(s)
Protéines bactériennes/métabolisme , Protéines de Drosophila , Lipoprotéines/métabolisme , Glycoprotéines membranaires/métabolisme , Récepteurs de surface cellulaire/métabolisme , Animaux , Groupe Borrelia burgdorferi/métabolisme , Cellules CHO , Cricetinae , Humains , Mycobacterium avium/métabolisme , Mycoplasma fermentans/métabolisme , Liaison aux protéines , Récepteur de type Toll-1 , Récepteur de type Toll-2 , Récepteur de type Toll-4 , Récepteurs de type Toll , Treponema pallidum/métabolisme
16.
J Acquir Immune Defic Syndr ; 22(1): 1-9, 1999 Sep 01.
Article de Anglais | MEDLINE | ID: mdl-10534141

RÉSUMÉ

Although nitric oxide (NO) production is increased in HIV-1-infected patients, and NO is known to inhibit the replication of several viruses, very little is known about the effects of NO on HIV-1 replication. In the present studies, we find that S-nitrosothiols (RSNOs), a class of NO donor compounds present in the human circulatory system, inhibit HIV-1 replication in acutely infected human peripheral blood mononuclear cells (PBMCs) and have an additive inhibitory effect on HIV-1 replication in combination with 3'-azido-3'-deoxythymidylate (AZT). RSNOs inhibit HIV-1 replication in acutely infected PBMCs at a step in the viral replicative cycle after reverse transcription, but before or during viral protein expression through a cGMP-independent mechanism. In the latently infected U1 cell line, NO donor compounds and intracellular NO production stimulate HIV-1 reactivation. These studies suggest that NO both inhibits HIV-1 replication in acutely infected cells and stimulates HIV-1 reactivation in chronically infected cells. Thus, NO may have a physiologic role in HIV-1 replication, and NO donor compounds, which have been used for decades in the treatment of coronary artery disease with limited toxicity, might be useful in the treatment of HIV-1 disease by inhibiting acute infection, reactivating latent virus, or both.


Sujet(s)
VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Agranulocytes/virologie , 2-Sulfanyl-éthanol , Monoxyde d'azote/physiologie , S-Nitrosothiols , Réplication virale/physiologie , Adulte , Agents antiVIH/pharmacologie , Lignée cellulaire , Cellules cultivées , GMP cyclique/métabolisme , ADN viral/effets des médicaments et des substances chimiques , Relation dose-effet des médicaments , Synergie des médicaments , Antienzymes/pharmacologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/effets des médicaments et des substances chimiques , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , Humains , Monoxyde d'azote/biosynthèse , Donneur d'oxyde nitrique/pharmacologie , Nitric oxide synthase/antagonistes et inhibiteurs , Nitric oxide synthase/biosynthèse , Composés nitrosés/pharmacologie , Pénicillamine/analogues et dérivés , Pénicillamine/pharmacologie , N-Acétyl-S-nitroso-pénicillamine , Transcription génétique , Protéines virales/biosynthèse , Réplication virale/effets des médicaments et des substances chimiques , Zidovudine/pharmacologie , oméga-N-Méthylarginine/pharmacologie
18.
J Immunol ; 163(2): 893-7, 1999 Jul 15.
Article de Anglais | MEDLINE | ID: mdl-10395684

RÉSUMÉ

Little is known regarding the mechanism by which T cells control intraabdominal abscess formation. Treating animals with polysaccharide A (PS A) from Bacteroides fragilis shortly before or after challenge protects against abscess formation subsequent to challenge with different abscess-inducing bacteria. Although bacterial polysaccharides are considered to be T cell-independent Ags, T cells from PS A-treated animals mediate this protective activity. In the present study, we demonstrate that CD4+ T cells transfer PS A-mediated protection against abscess formation, and that a soluble mediator produced by these cells confers this activity. Cytokine mRNA analysis showed that T cells from PS A-treated animals produced transcript for IL-2, IFN-gamma, and IL-10, but not for IL-4. The addition of IL-2-specific Ab to T cell lysates taken from PS A-treated animals abrogated the ability to transfer protection, whereas the addition of Abs specific for IFN-gamma and IL-10 did not affect protection. Finally, administration of rIL-2 to animals at the time of bacterial challenge prevented abscess formation in a dose-dependent manner. These data demonstrate that PS A-mediated protection against abscess formation is dependent upon a CD4+ T cell-dependent response, and that IL-2 is essential to this immune mechanism.


Sujet(s)
Abcès abdominal/immunologie , Interleukine-2/physiologie , Sepsie/immunologie , Abcès abdominal/prévention et contrôle , Transfert adoptif , Animaux , Spécificité des anticorps , Lymphocytes T CD4+/immunologie , Lymphocytes T CD4+/transplantation , Cytokines/antagonistes et inhibiteurs , Cytokines/biosynthèse , Cytokines/génétique , Cytokines/immunologie , Sérums immuns/pharmacologie , Injections péritoneales , Interleukine-2/usage thérapeutique , Mâle , Polyosides bactériens/administration et posologie , Polyosides bactériens/immunologie , ARN messager/biosynthèse , Rats , Rat Wistar , Protéines recombinantes/usage thérapeutique , Sepsie/prévention et contrôle , Solubilité
19.
J Gen Virol ; 80 ( Pt 6): 1519-1527, 1999 Jun.
Article de Anglais | MEDLINE | ID: mdl-10374971

RÉSUMÉ

Adenovirus (Ad) tropism is mediated in part through the fibre protein. The common coxsackie B virus and Ad receptor (CAR) was recently identified as the major receptor for subgroup C Ad serotype 5 (Ad5) and serotype 2 (Ad2) fibres. Effects of mutations in the Ad5 fibre gene were studied to assess domains of the fibre capsomer that could alter virus tropism without altering virus assembly and replication. All mutants that accumulated as fibre monomers failed to assemble with a penton base and proved lethal for Ad5 which suggests that the absence of infectious virions resulted in part from a defect in fibre penton base assembly. Cell binding capacity of all fibre mutants was investigated in cell binding competition experiments with adenovirions using CHO-CAR cells (CHO cells that have been transfected with CAR cDNA and express functional CAR). The results suggest that the R-sheet of the Ad5 fibre knob monomer contains binding motifs for CAR and that beta-strands E and F, or a region close to them, may also be involved in receptor recognition.


Sujet(s)
Adénovirus humains/métabolisme , Protéines de capside , Capside/génétique , Capside/métabolisme , Récepteurs viraux/métabolisme , Adénovirus humains/classification , Adénovirus humains/génétique , Animaux , Baculoviridae/génétique , Fixation compétitive , Cellules CHO , Protéine membranaire apparentée au récepteur des coxsackievirus et adénovirus , Cricetinae , Cellules HeLa , Humains , Luciferases/métabolisme , Mutagenèse dirigée , Phénotype , Plasmides/génétique , Protéines recombinantes/métabolisme , Spodoptera
20.
J Immunol ; 162(10): 6016-23, 1999 May 15.
Article de Anglais | MEDLINE | ID: mdl-10229841

RÉSUMÉ

The level of ongoing HIV-1 replication within an individual is critical to HIV-1 pathogenesis. Among host immune factors, the cytokine TNF-alpha has previously been shown to increase HIV-1 replication in various monocyte and T cell model systems. Here, we demonstrate that signaling through the TNF receptor family member, the lymphotoxin-beta (LT-beta) receptor (LT-betaR), also regulates HIV-1 replication. Furthermore, HIV-1 replication is cooperatively stimulated when the distinct LT-betaR and TNF receptor systems are simultaneously engaged by their specific ligands. Moreover, in a physiological coculture cellular assay system, we show that membrane-bound TNF-alpha and LT-alpha1beta2 act virtually identically to their soluble forms in the regulation of HIV-1 replication. Thus, cosignaling via the LT-beta and TNF-alpha receptors is probably involved in the modulation of HIV-1 replication and the subsequent determination of HIV-1 viral burden in monocytes. Intriguingly, surface expression of LT-alpha1beta2 is up-regulated on a T cell line acutely infected with HIV-1, suggesting a positive feedback loop between HIV-1 infection, LT-alpha1beta2 expression, and HIV-1 replication. Given the critical role that LT-alpha1beta2 plays in lymphoid architecture, we speculate that LT-alpha1beta2 may be involved in HIV-associated abnormalities of the lymphoid organs.


Sujet(s)
VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/croissance et développement , Lymphotoxine alpha/métabolisme , Monocytes/virologie , Récepteurs aux facteurs de nécrose tumorale/métabolisme , Facteur de nécrose tumorale alpha/métabolisme , Antigènes CD/métabolisme , Lignée cellulaire , Synergie des médicaments , Humains , Récepteur à la lymphotoxine-bêta , Lymphotoxine alpha/pharmacologie , Protéines membranaires/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Récepteur au facteur de nécrose tumorale de type II , Transduction du signal , Facteur de nécrose tumorale alpha/pharmacologie , Réplication virale/effets des médicaments et des substances chimiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...